The GLP is committed to full transparency. Download and review our Annual Report.

Turning white blood cells into ‘living cancer drugs’ with electric shocks

| | July 23, 2018

A promising new class of cancer treatments recruits the cells in our blood to fight tumors, using powerful gene-editing tools to transform a type of white blood cell — called a T cell — from an immune cell that normally targets bacterial or fungal infections into a living cancer drug.

The genetic alterations could boost immune systems to successfully fight cancers on their own. Researchers remove T cells from patients and slip new genes into the cells. After clinicians return the modified T cells to patients, the cells, like microscopic bloodhounds, lead the immune system on the hunt for tumors.

Disabled viruses, which inject genes into cells like a shot from a syringe, are the current standard.

Related article:  Immunotherapy could extend survival for patients with aggressive glioblastoma brain cancer

[Immunologist Alexander] Marson and his colleagues have developed a new, faster method to reprogram T cells, as they described [July 11] in the journal Nature. Rather than relying on viruses to deliver the genetic package, researchers jolted T cells with electricity. The shock relaxed the membranes that surround the cells, making them receptive to new genetic material.

“It’s a turning point,” said Vincenzo Cerundolo, director of the Human Immunology Unit at Oxford University.

He predicts cheaper therapies and much faster development times — as swiftly as a week, rather than the months required to manufacture a virus.

Read full, original post: With new genes and an electric shock, scientists turn immune cells against cancer

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend